Evidence-Based Practice: Evaluating a New Supplement for Sarcopenia
A 70-year-old male with sarcopenia asks about a new supplement containing beta-hydroxy-beta-methylbutyrate (HMB) that he saw advertised. He currently exercises with resistance training twice weekly and consumes 0.8 g/kg protein daily (weight 70 kg). He wants to know if the supplement will help him gain muscle. You need to critically appraise the evidence and provide a recommendation.
1. How would you critically appraise the evidence for HMB supplementation in sarcopenia? What key factors would you consider?
Read the worked answer
Critical appraisal: 1) Search for systematic reviews and randomized controlled trials (RCTs) on HMB and sarcopenia in older adults. 2) Assess study quality: randomization, blinding, sample size, duration, and outcome measures (muscle mass, strength, physical function). 3) Consider heterogeneity: some studies show benefits when combined with resistance training, but effects are modest. 4) Check for conflicts of interest (many studies funded by industry). 5) Evaluate generalizability to this patient (age, sex, comorbidities). 6) Compare with established interventions: adequate protein intake (1.0-1.2 g/kg/day) and resistance training are first-line. Current evidence suggests HMB may have small benefits on muscle mass and strength when combined with exercise, but evidence is not strong enough to recommend as a sole therapy. Grade evidence using GRADE or similar. Conclusion: HMB is likely safe but not essential; prioritize protein optimization and exercise.
2. What recommendation would you give the patient, and how would you communicate the evidence?
Read the worked answer
Recommendation: 1) Increase dietary protein to 1.0-1.2 g/kg/day (70-84 g/day) by adding protein-rich foods at each meal (e.g., Greek yogurt, eggs, lean meats, legumes). 2) Continue resistance training twice weekly, possibly increase to 3 times. 3) Explain that HMB supplement has limited evidence; it may provide small benefit but is not a substitute for protein and exercise. 4) Discuss cost and potential risks (generally safe, but unknown long-term). 5) Shared decision-making: respect patient's autonomy; if he wants to try, suggest a reputable brand and monitor for effects. 6) Provide written resources. Communication: use plain language, avoid jargon, explain evidence in terms of benefits and harms, and set realistic expectations. Schedule follow-up to assess progress.